Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 0.00 (0.00%)
Spread: 0.50 (10.00%)
Open: 5.25
High: 5.25
Low: 5.00
Prev. Close: 5.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line

Wed, 27th Mar 2024 16:13

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Spectra Systems Corp - Providence, Rhode Island-based authentication technology provider - Reports revenue in 2023 edged up to USD20.2 million from USD19.6 million the year prior. Net income was USD6.0 million, slightly lower than USD6.1 million last time, with diluted earnings per share of 0.13 pence compared to 0.12p. Pays annual dividend of USD0.116 per share, up from USD0.115. Says cash position "remains strong", with cash generation driven by sensor development milestones and prepayments, record sales of covert materials to a central bank, and strong optical materials sales. Believes "that the company is on track to achieve record earnings in 2024."

----------

Infrastructure India PLC - infrastructure fund investing directly into assets in India - Says pretax loss in the six months to September 30 halves to GBP31.6 million from GBP62.2 million the year prior. Basic and diluted loss per share totals 4.77 pence, compared to 5.72p. Says value of investments was GBP99.6 million as at September 30, down from GBP194.1 million the year before.

----------

Metals Exploration PLC - Philippines-focused gold producer - Makes last payment due to the lenders under the mezzanine debt facilities on Monday on the basis of the lower interest rate of 7%, as opposed to 15%, which the company believes should apply under such facilities. Says amount outstanding on the group's senior facility as at Monday stands at USD2,629. Metals Exploration says it has agreed the 7% rate with the majority mezzanine lender, MTL Luxembourg SA. But explains it has been unable to reach agreement as yet, with the minority 29% mezzanine debt lenders, Runruno Holdings Ltd and D & A Holdings Ltd. RHL Group advisers have stated their belief that the higher 15% rate is applicable, which potentially amounts to an additional USD1.9 million owed. But Metals exploration disputes this. Discussions continue. Intends to apply future free cash generated from operations to fund ongoing growth opportunities based on MTL's proven operating track record in the Philippines.

----------

Allergy Therapeutics PLC - Sussex, England-based biotechnology company - Extends cash runway until the first quarter of 2025 following talks with major shareholders SkyGem Acquisition Ltd and Southern Fox Investments Ltd. Lenders agree that a further GBP15 million from the existing GBP40 million amended loan facility, announced on December 27, may be drawn down from the second quarter of 2024. Further, will issue warrants to the lenders following each drawdown under the amended loan facility, entitling the holders to subscribe for new shares at a price of 4 pence each. The entitlement to warrants will be 25 warrants for each GBP1 drawn down under the amended loan facility with a maximum of 1.00 billion warrants. The warrants will be exercisable in whole or in part from July 1 until January 15, 2027. Further, reports pretax loss in the six months to December 31 widens to GBP14.9 million from GBP8.2 million the year prior. Diluted loss per share totals 0.58p compared to LPS of 1.29p. Revenue falls to GBP33.6 million from GBP39.9 million. Explains the decrease in revenue is due to previously reported manufacturing capacity that needed to be allocated to investigational medicinal product batches for use in clinical trials and the ongoing programme of continuous improvement across the supply chain and quality systems paving the way for increased capacity. Demand for the company's products continues to be robust.

----------

Quartix Technologies PLC - Newtown, Wales-based vehicle tracking system provider - Issues trading statement ahead of Wednesday's annual general meeting. Says trading for the first two months of 2024 has been consistent with meeting market expectations for the year. Notes new unit subscriptions for the first quarter of 2024 are expected to be around 10% higher annually. Growth in new subscriptions continues to be led by France and Continental Europe. Further, advises Chief Financial Officer Emily Rees resigns to pursue opportunities outside the company.

----------

Microsaic Systems PLC - Surrey-based developer of real-time mass spectrometers - Reports that having passed quality control specifications, shipments of existing MicroTox reagent stock have begun to meet the demand from clients that are operating Modern Water instruments currently in service. Says stock levels are sufficient to meet this demand until restarted production output from the York facility passes testing and quality control for shipping, as scheduled for April. Further, agrees terms with GX Group, based in Usk Wales, for the continued manufacturing and further development of continuous toxicity monitoring instruments previously sold by the Modern Water business. Acting Executive Chair Bob Moore says: "The combination of Modern Water and Microsaic technologies is underway as planned."

----------

Kingfisher PLC - retailer which owns B&Q and Castorama - Instructs Goldman Sachs International to start the second tranche of the share buy back programme. This will start Wednesday and end no later than June 14. The maximum amount allocated to the tranche will be no greater than GBP50 million. Forms part of overall GBP300 million buy back.

----------

Solid State PLC - Redditch, England-based supplier & design-in manufacturer of computing, power, and communications products - Issues trading update to year ending March 31. Reports a record year with a strong trading performance towards the end of the year. Revenue and adjusted pretax profit are expected to be ahead of consensus expectations. This reflects the recognition of Systems revenue on deliveries in the current financial year. This had previously been expected to be recognised in the financial year to March 2025.

----------

Leeds Group PLC - West Yorkshire, England-based textile manufacturing company - Completes sale of Hemmers-Itex Textil Import Export GmbH. Explains the disposal is deemed to be a sale that divests the company of all, or substantially all of its trading businesses. Therefore, with effect from Tuesday, Leeds is regarded as an AIM Rule 15 cash shell.

----------

LPA Group PLC - Essex-based LED lighting and electro-mechanical systems maker - Issues trading statement at Wednesday's annual general meeting. States first quarter trading has been as anticipated. "Sales levels were largely on target, good order books remain and we are seeing an increased level of activity particularly." Cautions the second quarter "will be affected by late cable shipments which are now coming around the Cape but this will be made up in our third quarter." LPA says "it is clear that the return to profitability will be in our FY25 as some of the growth and profit we were planning for FY24 will have been deferred a further year."

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
18 Mar 2014 06:31

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
17 Mar 2014 15:51

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
12 Mar 2014 11:33

Allergy Therapeutics Reports Profits, Revenues For Year To End-September

LONDON (Alliance News) - Allergy Therapeutics PLC Wednesday reported revenues of GBP40.5 million and a profit of GBP890,000 for the 12 months to September 30, 2013. The company's financial year runs until the end of June, but it has provided additional figures for the year to end-September

Read more
19 Feb 2014 13:21

Allergy Therapeutics gets green light for hay fever study in Canada

Speciality pharmaceuticals firm Allergy Therapeutics has received the approval from the Canadian health regulators to submit a full clinical trial application for a new study of its hay fever vaccine. Following on from successful discussions held with the US Food and Drug Administration previously,

Read more
19 Feb 2014 09:12

Allergy Therapeutics' Hay Fever CTA Approved By Health Canada

LONDON (Alliance News) - Allergy Therapeutics PLC said Wednesday that the Canadian health authority has approved its proposal to submit a full clinical trial application for an efficacy study for Pollinex Quattro Grass MATA MPL (0.5ml). The speciality pharma firm said its proposal for a new

Read more
27 Jan 2014 09:57

Allergy Therapeutics Says Positive Ragweed Allergy Treatment Published

LONDON (Alliance News) - Allergy Therapeutics PLC said Monday that results from its Phase IIb clinical trial of its Pollinex Quattro ragweed allergy treatment have been published in the Journal of Allergy and Clinical Immunology. The trial showed that the treatment was safe and effective in

Read more
20 Nov 2013 10:05

Allergy Therapeutics Revenues Up 16%, Appoints New R&D Director

Read more
20 Nov 2013 07:52

AIM IN BRIEF: Rangers FC Appoints Graham Wallace As CEO

Read more
20 Nov 2013 07:38

Allergy Therapeutics boosts sales, gains market share

Allergy vaccine developer Allergy Therapeutics reported higher sales and revenue since July and said it was gaining share in all its main markets. The group said net revenues rose 16% in the first four months of this financial year against the same period last year while gross sales at constant cur

Read more
16 Sep 2013 12:53

Allergy Therapeutics Hit By Challenging Conditions As Profit Declines

Read more
16 Sep 2013 12:13

Monday broker round-up

AEC Education: WH Ireland places both its target price (prev.: 11p) and its recommendation under review. Aggreko: Citi reduces target price from 2100p to 2000p leaving its buy recommendation unaltered. Allergy Therapeutics: Panmure Gordon lowers target price from 18p to 16p, while keeping its buy

Read more
27 Dec 2012 14:29

Allergy Therapeutics ends contract with Lincoln Medical

Allergy Therapeutics has terminated its agreement with Lincoln Medical for the distribution rights of Anapen in a number of countries, following a recall of the drug in the UK. The pharmaceutical company said Lincoln Medical undertook a voluntary recall of all unexpired units of Apapen, an adrenali

Read more
10 Dec 2012 16:25

Chamberlin Chairman invests 75k

Castings and engineering group Chamberlin announced on Monday that its Chairman has topped up his stake in the company twice over the couple of weeks. Keith Butler-Wheelhouse acquired a total of 44,500 Chamberlin ordinary shares through his family trust, BW Family Limited (BWFL), representing 0.56%

Read more
9 Nov 2012 16:30

Shanks Chairman buys shares as profits fall

The Chairman of Shanks Group, the FTSE 250 waste management firm, has bought 60,000 shares in the firm following the company's announcement that half year profits fell by 29 per cent. Chairman Adrian Auer purchased the shares at 82.93p each for a total of £49,758. On Thursday the company revealed

Read more
3 Aug 2012 11:45

Small caps round-up: Allergy, XCAP, Totally...

Allergy Therapeutics, a specialist pharmaceutical company focused on allergy vaccination, has welcomed the Food and Drugs Association's decision to lift the clinical hold on the company's grass pollen allergy vaccine clinical development programme, with immediate effect. Allergy has gained approval

Read more

Quickpicks are a member only feature

Login to your account